Compare AEF & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEF | VYGR |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.7M | 232.4M |
| IPO Year | N/A | 2015 |
| Metric | AEF | VYGR |
|---|---|---|
| Price | $6.89 | $4.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 92.5K | ★ 474.3K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | ★ $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.78 |
| P/E Ratio | $8.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.40 | $2.65 |
| 52 Week High | $5.53 | $6.55 |
| Indicator | AEF | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 54.46 |
| Support Level | $6.67 | $3.74 |
| Resistance Level | $7.11 | $4.51 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 68.84 | 84.94 |
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.